Savara Announces Chief Financial and Administrative Officer Transition

Savara Inc. announced that Chief Financial and Administrative Officer Dave Lowrance is stepping down effective July 15, 2026, for health-related reasons. His responsibilities will be split, with Chief Operating Officer Robert Lutz assuming the CFO role while administrative duties are distributed among senior leadership. Lutz brings over two decades of pharmaceutical industry experience and previously served as CFO at iBio and Strongbridge Biopharma.

06/08/2026, 4:05 PM • Benzinga

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3rd. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

05/27/2026, 4:05 PM • Benzinga

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19th at 10:00am ET in New York. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

05/11/2026, 4:05 PM • Benzinga

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. announced it received a Day 74 Letter from the FDA indicating no Advisory Committee meeting is planned for MOLBREEVI's Biologics License Application, with a PDUFA target action date of August 22, 2026. The company has submitted a Marketing Authorization Application to the European Medicines Agency and remains on track to submit to the UK's MHRA by end of Q1 2026. MOLBREEVI, a recombinant GM-CSF treatment for autoimmune PAP, has received Fast Track and Breakthrough Therapy designations from the FDA.

03/06/2026, 4:05 PM • Benzinga

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced that its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The company is focused on rare respiratory diseases with its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

03/04/2026, 4:05 PM • Benzinga

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and fireside chats at two upcoming investor healthcare conferences. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

02/04/2026, 4:05 PM • Benzinga

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Savara, Inc. for potential breach of fiduciary duties by its board of directors. The investigation concerns allegations that Savara failed to disclose that its MOLBREEVI BLA lacked sufficient information regarding chemistry, manufacturing, and controls, making FDA approval unlikely. On May 27, 2025, the FDA issued a refusal to file letter, causing Savara's stock to plummet 31.69% to $1.94 per share. The class action covers the period from March 7, 2024 to May 23, 2025.

01/24/2026, 11:38 AM • GlobeNewswire

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will present at the 44th Annual J.P. Morgan Healthcare Conference. The company's lead program, MOLBREEVI, is a Phase 3 development treatment for autoimmune pulmonary alveolar proteinosis.

12/17/2025, 8:05 AM • Benzinga

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting one-on-one meetings and fireside chats.

11/20/2025, 4:05 PM • Benzinga

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against Savara Inc. for allegedly making false and misleading statements about their BLA (Biologics License Application) for MOLBREEVI, which was deemed insufficient by the FDA and likely to require additional capital.

11/07/2025, 2:22 AM • Benzinga

SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process, with a November 7, 2025 lead plaintiff deadline.

11/05/2025, 8:57 PM • GlobeNewswire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting meetings and fireside chats to discuss their lead program MOLBREEVI.

11/03/2025, 4:05 PM • Benzinga

SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm is alerting Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process.

11/02/2025, 6:47 PM • GlobeNewswire

SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's Biologics License Application and FDA approval timeline.

10/30/2025, 7:32 PM • GlobeNewswire

DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts investors about potential securities fraud class action lawsuits for four companies, highlighting alleged misleading statements and financial irregularities during specific time periods.

10/30/2025, 1:46 PM • GlobeNewswire